Mayra Pozo
Nurse Practitioner · New York, NYNPI 1578193447
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (59.8%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 12 manufacturers reported payments, led by Amneal Pharmaceuticals LLC at 33.1% of the total. 2025 is the largest year on record at $7,143, 7.7 times the $923 reported in 2021. Among nurse practitioner clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 250 payments — averaging $55.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amneal Pharmaceuticals LLC$5K
- Abbott$3K
- Medtronic$2K
- MDD US Operations, LLC$2K
- Neurocrine Biosciences, Inc.$1K
- Acadia Pharmaceuticals Inc$559
- plus $922 from 6 others
What the payments were for
- Consulting fees$4,33231%
- Speaking & faculty fees$370%
- Travel & lodging$9467%
- Food & beverage$8,25760%
- Education$2382%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amneal Pharmaceuticals LLC | 18 | $4,570 |
| Abbott | 70 | $3,408 |
| Medtronic | 32 | $1,752 |
| MDD US Operations, LLC | 63 | $1,545 |
| Neurocrine Biosciences, Inc. | 10 | $1,054 |
| Acadia Pharmaceuticals Inc | 38 | $559 |
| AbbVie | 2 | $272 |
| Boston Scientific | 2 | $255 |
| Teva Pharmaceuticals USA, Inc. | 11 | $211 |
| Insightec,inc | 1 | $93 |
| UCB, Inc. | 2 | $52 |
| Jazz Pharmaceuticals Inc. | 1 | $38 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CREXONT$4,332
- INFINITY$1,944
- INGREZZA$953
- PERCEPT PC BRAINSENSE$937
- Duopa$272
- GENERAL DBS$104
How this compares
$13,810 in reported general payments places this provider in the 95th percentile of 4,112 nurse practitioner providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 51 | $408,442 |
| GocovriAmantadine Hcl | 92 | $364,492 |
| IngrezzaValbenazine Tosylate | 14 | $159,704 |
| RytaryCarbidopa/Levodopa | 83 | $117,797 |
| NourianzIstradefylline | 12 | $44,117 |
| NeuproRotigotine | 24 | $29,888 |
| Rasagiline Mesylate | 93 | $22,942 |
| InbrijaLevodopa | 15 | $21,320 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 420 | $17,030 |
| OngentysOpicapone | 12 | $12,639 |
| Rivastigmine | 38 | $6,209 |
| AmantadineAmantadine Hcl | 45 | $4,145 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 81 | $3,715 |
| Selegiline Hcl | 23 | $2,607 |
| Ropinirole ErRopinirole Hcl | 14 | $1,914 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncNuplazid | $559 | $408,44251 claims |
| MDD US Operations, LLCGocovri | $1,545 | $364,49292 claims |
| Neurocrine Biosciences, Inc.Ingrezza, Ongentys | $1,054 | $172,34326 claims |
| Amneal Pharmaceuticals LLCRytary | $4,570 | $117,79783 claims |
| UCB, Inc.Neupro | $52 | $29,88824 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,112 nurse practitioner providers in New York.
Other nurse practitioner in New York
- Patricia McGoldrickNew York$202K
- Jodi LogerfoNew York$48K
- Aileen FerrickNew York$26K
- Tsz Isabel WongNew York$25K
- Chris BustamanteNew York$22K
- Janet JohnsonNew York$12K
- Rachel RankinNew York$10K
- Richelle CassellNew York$10K
- Michelle DartSyracuse$95K
- Susan KreppelWilliamsville$67K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.